Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy

Journal of the National Cancer Institute

Volumn 107, Issue 7, 2015, Pages

  Challagundla, Kishore B ^a,b   Wise, Petra M ^a,b   Neviani, Paolo ^a,b   Chava, Haritha ^a,b   Murtadha, Mariam ^a,b   Xu, Tong ^b   Kennedy, Rebekah ^a   Ivan, Cristina ^c   Zhang, Xinna ^c   Vannini, Ivan ^d   Fanini, Francesca ^d   Amadori, Dino ^d   Calin, George A ^c   Hadjidaniel, Michael ^a   Shimada, Hiroyuki ^e   Jong, Ambrose ^a   Seeger, Robert C ^a   Asgharzadeh, Shahab ^a,e   Goldkorn, Amir ^b   Fabbri, Muller ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MICRORNA 155; MICRORNA 21; MICRORNA 29A; TELOMERIC REPEAT BINDING FACTOR 1; TOLL LIKE RECEPTOR 8; ANTINEOPLASTIC AGENT; MICRORNA; MIRN155 MICRORNA, HUMAN; MIRN21 MICRORNA, HUMAN; TELOMERE BINDING PROTEIN; TERF1 PROTEIN, HUMAN; TLR8 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; COCULTURE; CONTROLLED STUDY; EXOSOME; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; MONOCYTE; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT; CELL COMMUNICATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; METABOLISM; XENOGRAFT;

ANTINEOPLASTIC AGENTS; CELL COMMUNICATION; CISPLATIN; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; EXOSOMES; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MICRORNAS; MONOCYTES; NEUROBLASTOMA; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION; TELOMERE-BINDING PROTEINS; TOLL-LIKE RECEPTOR 8; TUMOR MICROENVIRONMENT;

EID: 84939499533     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv135     Document Type: Article

References (44)

1. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol. 2009;27(2):289-297.
2. Deyell RJ, Attiyeh EF. Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma. Cancer Genet. 2011;204(3):113- 121.
3. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children's oncology group study. J Clin Oncol. 2009;27(7):1007-1013.
4. Schmidt ML, Lal A, Seeger RC, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: A Children's Cancer Group Study. J Clin Oncol. 2005;23(27):6474-6480.
5. George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol. 2005;23(27):6466-6473.
6. Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010;363(14):1313- 1323.
7. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203-216.
8. Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial. Lancet Oncol. 2008;9(3):247-256.
9. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219-234.
10. Asgharzadeh S, Salo JA, Ji L, et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol. 2012;30(28):3525-3532.
11. Ara T, Song L, Shimada H, et al. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res. 2009;69(1):329-337.
12. Ara T, Nakata R, Sheard MA, et al. Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma. Cancer Res. 2013;73(13):3852-3864.
13. Zhang QW, Liu L, Gong CY, et al. Prognostic significance of tumor-associated macrophages in solid tumor: A meta-analysis of the literature. PLoS One. 2012;7(12):e50946.
14. Colvin EK. Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front Oncol. 2014;4:137.
15. Franklin RA, Liao W, Sarkar A, et al. The cellular and molecular origin of tumor-associated macrophages. Science. 2014;344(6186):921-925.
16. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003;113(6):673-676.
17. Chen Y, Stallings RL. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res. 2007;67(3):976-983.
18. Fabbri M, Paone A, Calore F, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A. 2012;109(31):E2110-E2116.
19. Asgharzadeh S, Pique-Regi R, Sposto R, et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst. 2006;98(17):1193-1203.
20. Gridley DS, Andres ML, Slater JM. Enhancement of prostate cancer xenograft growth with whole-body radiation and vascular endothelial growth factor. Anticancer Res. 1997;17(2A):923-928.
21. O'Connell RM, Taganov KD, Boldin MP, et al. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A. 2007;104(5):1604-1609.
22. Melo SA, Sugimoto H, O'Connell JT, et al. Cancer exosomes perform cellindependent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26(5):707-721.
23. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809.
24. Li P, Grgurevic S, Liu Z, et al. Signal transducer and activator of transcription- 3 induces MicroRNA-155 expression in chronic lymphocytic leukemia. PLoS One. 2013;8(6):e64678.
25. Escobar T, Yu CR, Muljo SA, et al. STAT3 activates miR-155 in Th17 cells and acts in concert to promote experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2013;54(6):4017-4025.
26. Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs. 2010;13(6):394-403.
27. Pardanani A, Tefferi A. Targeting myeloproliferative neoplasms with JAK inhibitors. Curr Opin Hematol. 2011;18(2):105-110.
28. Kosaka N, Iguchi H, Yoshioka Y, et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010;285(23):17442- 17452.
29. Wesbuer S, Lanvers-Kaminsky C, Duran-Seuberth I, et al. Association of telomerase activity with radio- and chemosensitivity of neuroblastomas. Radiat Oncol. 2010;5:66.
30. Dinami R, Ercolani C, Petti E, et al. miR-155 drives telomere fragility in human breast cancer by targeting TRF1. Cancer Res. 2014;74(15):4145-4156.
31. Smogorzewska A, van Steensel B, Bianchi A, et al. Control of human telomere length by TRF1 and TRF2. Mol Cell Biol. 2000;20(5):1659-1668.
32. Kocak H, Ackermann S, Hero B, et al. Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma. Cell Death Dis. 2013;4:e586.
33. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569-579.
34. Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-659.
35. Diotti R, Loayza D. Shelterin complex and associated factors at human telomeres. Nucleus. 2011;2(2):119-135.
36. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet. 2008;42:301-334.
37. Ohali A, Avigad S, Ash S, et al. Telomere length is a prognostic factor in neuroblastoma. Cancer. 2006;107(6):1391-1399.
38. Deville L, Hillion J, Pendino F, et al. hTERT promotes imatinib resistance in chronic myeloid leukemia cells: Therapeutic implications. Mol Cancer Ther. 2011;10(5):711-719.
39. Yamada O, Ozaki K, Furukawa T, et al. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. Cell Signal. 2011;23(7):1119-1127.
40. Goldblatt EM, Erickson PA, Gentry ER, et al. Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab. Breast Cancer Res Treat. 2009;118(1):21-32.
41. Guo XL, Ma NN, Zhou FG, et al. Up-regulation of hTERT expression by lowdose cisplatin contributes to chemotherapy resistance in human hepatocellular cancer cells. Oncol Rep. 2009;22(3):549-556.
42. Mukherjee S, Bhattacharya RK, Roy M. Targeting protein kinase C (PKC) and telomerase by phenethyl isothiocyanate (PEITC) sensitizes PC-3 cells towards chemotherapeutic drug-induced apoptosis. J Environ Pathol Toxicol Oncol. 2009;28(4):269-282.
43. Smith V, Dai F, Spitz M, et al. Telomerase activity and telomere length in human tumor cells with acquired resistance to anticancer agents. J Chemother. 2009;21(5):542-549.
44. Domcke S, Sinha R, Levine DA, et al. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126.